*仅供医学专科东说念主士阅读参考亚洲色图 无码

消化系统商量提要标题速递

撰文丨鹿其临

2024年9月13日-17日，欧洲肿瘤内科学会（ESMO）年会将于在西班牙巴塞罗那召开，看成肿瘤内科最高限制的外洋嘉会，波及肺癌、、消化说念肿瘤、泌尿生殖系统肿瘤等范围的多项商议届时都将久了最新阐明。

当今，ESMO官网照旧公布本次入选大会的LBA、Oral（O）和Mini oral（MO）标题，医学界特将部分消化系统肿瘤商量提要标题进行整理，分为、肠癌、肝细胞癌、胰腺癌、胃肠说念间质瘤，以飨读者。（注：本文不分先后限定）

胃癌

提要号：LBA58

A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup trial of AGITG， TROG， EORTC and CCTG

随即III期AGITG-TOPGEAR磨砺：围术期化疗（围术期CT）±术前放化疗（术前CRT）赈济可切除胃癌，来自AGITG、TROG、EORTC和CCTG组间磨砺的最终恶果

报告内行：Trevor Leong（澳大利亚・墨尔本）

提要号：LBA59

Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Final Results of the IKF-AIO-Moonlight trial

IKF-AIO-Moonlight磨砺的最终恶果：改动FOLFOX±纳武利尤单抗＋伊匹木单抗 vs FLOT+纳武利尤单抗赈济既往未经治的晚期或革新性胃或胃食管交壤（G/GEJ）腺癌患者

报告内行：Sylvie Lorenzen（德国・慕尼黑）

提要号：LBA60

Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)

III期商议：SHR-1701 vs抚慰剂聚合化疗一线赈济HER2阴性G/GEJ腺癌

报告内行：彭智（北京大学肿瘤病院）

提要号：1400O

Final overall survival for the phase 3， KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced， unresectable or metastatic G/GEJ adenocarcinoma

III期KEYNOTE-811商议的最终OS数据：帕博利珠单抗+曲妥珠单抗+化疗赈济HER2+晚期、不成切除或革新性G/GEJ腺癌

报告内行：Yelena Y. Janjigian（好意思国・纽约）

提要号：609O

CLDN18.2 targeted antibody-drug conjugate (ADC)， SHR-A1904， in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): a phase 1 study

I期商议：靶向CLDN18.2 ADC药物，SHR-A1904用于G/GEJ癌患者

报告内行：徐瑞华（中山大学肿瘤防治中心）

提要号：1401O

Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal， gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)

DESTINY-Gastric03（DG-03）商议：德曲妥珠单抗（T-DXd）单药赈济及聚合赈济晚期/革新性HER2阳性（HER2+）食管、G/GEJ腺癌患者

报告内行：Yelena Y. Janjigian（好意思国・纽约）

提要号：1402MO

An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophage

一项外洋商议：评估病理响应以教唆胃食管癌的援手FLOT化疗

报告内行：Margaret M. Lee（澳大利亚・盒子山）

肠癌

结肠癌

提要号：LBA24

Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2

局部晚期dMMR结肠癌的新援手免疫疗法：来自NICHE-2商议的3年无病生涯期（DFS）

报告内行：Myriam Chalabi（荷兰・阿姆斯特丹）

提要号：63O

Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial

在PEGASUS磨砺中，丁香五色月与术后残留疾病和ctDNA情状商量的II期T4N0/III期结肠癌的转录特征

报告内行：Enzo Medico（意大利・坎迪奥洛）

提要号：503O

Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study

新援手纳武利尤单抗（nivo）聚合relatlimab（rela）赈济dMMR结肠癌患者：NICHE-3商议恶果

报告内行：Peter G. De Gooyer（荷兰・阿姆斯特丹）

提要号：512O

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III， Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial

阿司匹林援手赈济PIK3CA突变结肠癌患者——III期、前瞻性随即抚慰剂对照的多中心SAKK 41/13磨砺

报告内行：Ulrich Güller（瑞士・图恩湖）

结直肠癌

提要号：LBA25

Randomized Phase III trial of Ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)

随即III期德国AIO（AIO-KRK-0316）的RAMTAS/IKF643磨砺： 雷莫西尤单抗聚合TAS102（Trifluridin/Tipiracil）vs TAS102单药赈济既往收受赈济后复发革新性结直肠癌（mCRC）

报告内行：Stefan Kasper-Virchow（德国・埃森）

提要号：LBA26

SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)亚洲色图 无码

SOLARIS（Alliance A021703）：一项多中心双盲III期随即临床磨砺（RCT），探索维生素D（VitD）聚合规范化疗、贝伐珠单抗（bev）赈济既往未经赈济的mCRC患者

报告内行：Kimmie Ng（好意思国・波士顿）

提要号：502O

Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial

帕博利珠单抗聚合CAPOX和贝伐珠单抗赈济微卫星褂讪mCRC和高免疫浸润患者：FFCD 1703 POCHI磨砺的初步恶果

报告内行：David Tougeron（法国・普瓦捷）

提要号：504O

IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: results of the colorectal cancer cohort

IMHOTEP II期磨砺恶果：帕博利珠单抗新援手赈济dMMR/MSI CRC患者

报告内行：Christelle De la Fouchardiere（法国・马赛）

提要号：505O

Sotorasib (soto)， panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase 1b CodeBreaK 101 study

索托拉西布（soto）、panitumumab（pani）和FOLFIRI在KRAS G12C突变的mCRC一线赈济中的行使：CodeBreaK 101 Ib期商议的安全性和灵验性分析

报告内行：Salvatore Siena（意大利・米兰）

提要号：506O

Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment- an analysis of eleven randomized trials by AIO and GONO

评估未切除的mCRC一线赈济中的疾病阐明风险，以教唆发射学评估断绝——一项由AIO和GONO进行的11项随即磨砺分析

报告内行：Marco M. Germani（意大利・比萨）

提要号：507O

Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer. Final results of the phase II randomized multicenter LEANOX trial

以轻体重计较的奥沙利铂剂量对III期结直肠癌援手赈济中神经毒性的影响：LEANOX II期随即多中心磨砺的最终恶果

报告内行：Eric Assenat（法国・蒙彼利埃）

提要号：511MO

Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized phase II CITRIC trial

在轮回肿瘤DNA（ctDNA）筛选的mCRC患者中，第三次使用西妥昔单抗（Cet）和伊立替康再挑战：随即II期CITRIC磨砺

报告内行：Cristina Santos Vivas（西班牙・卢斯皮塔莱特德略夫雷加特）

提要号：513MO

Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1， an open-label， phase 1b/2 study

埃万妥单抗聚合FOLFOX或FOLFIRI赈济mCRC患者：来自一项洞开标签、Ib/II期OrigAMI-1商议恶果

报告内行：Filippo Pietrantonio（意大利・米兰）

提要号：514MO

The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)

依沃西单抗±ligufalimab+FOLFOXIRI一线赈济mCRC的疗效和安全性

报告内行：邓艳红（中山大学附庸第六病院）

提要号：515MO

Encorafenib + Cetuximab (EC) + FOLFIRI for BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC): Updated Results From the BREAKWATER Safety Lead-In (SLI)

Encorafenib+西妥昔单抗（EC）+FOLFIRI赈济BRAF V600E突变mCRC ：来自BREAKWWATER安全性先行磨砺（SLI）最新恶果

报告内行：Josep Tabernero（西班牙・巴塞罗纳）

提要号：516MO

Zanidatamab (Zani) + Chemotherapy (CT) in First-Line (1L) Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Advanced/Metastatic Colorectal Cancer (mCRC)

Zanidatamab（Zani）+化疗（CT）一线赈济HER2阳性晚期/mCRC

报告内行：Sun Young Rha（韩国・首尔）

提要号：518MO

Update analysis of the randomized phase II study comparing FOLFIRI plus (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)

随即II期WJOG9216G（RECAST）商议的最新分析：FOLFIRI+雷莫西尤单抗（RAM）vs FOLFXIRI+RAM一线赈济mCRC患者

报告内行：Kentaro Yamazaki（日本・静冈）

直肠癌

提要号：508MO

Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial

早期直肠腺癌的器官保留：Opera随即手术磨砺的5年恶果

报告内行：Syrine Ben Dhia（法国・尼斯)

提要号：509O

Total Neoadjuvant Treatment (TNT) with Non-Operative Management (NOM) for Proficient Mismatch Repair Locally Advanced Rectal Cancer (pMMR LARC): First Results of NO-CUT Trial

关于熟悉pMMR局部晚期直肠癌（pMMR LARC）罗致全程新援手赈济（TNT）与非手术赈济（NOM）：NO-CUT磨砺的初次恶果

报告内行：Alessio Amatu（意大利・米兰）

肝细胞癌

提要号：LBA3

Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study

经动脉化疗栓塞（TACE）±仑伐替尼（len）+帕博利珠单抗（pembro）赈济中期肝细胞癌（HCC）：III期LEAP-012商议

报告内行：Josep Llovet（西班牙・巴塞罗纳）

提要号：LBA38

Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC): a randomized， open-label， phase 2/3 study (DUBHE-H-308)

Iparomlimab和tuvonralimab（QL1706）聚合贝伐珠单抗和/或化疗用于晚期HCC 的一线赈济： 一项随即、洞开标签、II/III期商议（DUBHE-H-308）

报告内行：秦叔逵（南京天印山病院）

提要号：LBA39

Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)

IMbrave050的最新疗效和安全性数据：阿替利珠单抗（atezo）+贝伐珠单抗（bev）援手赈济与主动监测在切除或消融的高危HCC患者的III期商议

报告内行：Adam Yopp（好意思国・达拉斯）

提要号：LBA40

Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

III期ALTN-AK105-III-02商议的主要恶果：派安普利单抗vs索拉非尼聚合安罗替尼一线赈济aHCC

报告内行：周俭（复旦大学附庸中山病院）

提要号：947MO

Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

III期HIMALAYA商议：tremelimumab聚合度伐利尤单抗赈济uHCC的的5年总生涯期（OS）和肿瘤响应测量的OS

报告内行：Lorenza Rimassa（意大利・罗扎诺）

提要号：965MO

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): expanded analyses from CheckMate 9DW

纳武利尤单抗（NIVO）聚合伊匹木单抗（IPI）vs仑伐替尼（LEN）或索拉非尼（SOR）看成不成切除HCC的一线赈济：CheckMate 9DW的彭胀分析

报告内行：Thomas Decaens（法国・拉特龙什）

提要号：LBA62

Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS/PRODIGE 44

可边际切除胰腺癌（BRPC）术前改动FOLFIRINOX（mFOLFIRINO）±放化疗（CRT）：PANDAS/PRODIGE 44随即II期磨砺恶果

报告内行：Aurélien Lambert（法国・旺多洛夫南锡）

提要号：LBA63

A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy

伊立替康脂质体聚合S-1 vs伊立替康脂质体聚合5-氟尿嘧啶二线赈济吉西他滨化疗后革新性PC患者的随即I/II期商议

报告内行：Anne M. Gehrels（荷兰・阿姆斯特丹）

提要号：608O

Preliminary safety and clinical activity of ASP3082， afirst-in-class， KRAS G12D selective protein degrader in adults with advanced pancreatic (PC)， colorectal (CRC)， and non-small cell lung cancer (NSCLC)

ASP3082（first-in-class的KRAS G12D聘任性卵白质降解剂）在患有晚期PC、CRC和（NSCLC）的成东说念主中的初步安全性和临床活性

报告内行：Wungki Park（好意思国・纽约）

提要号：1504MO

Phase 2 Trial of Pembrolizumab and OLApaRib (POLAR) Maintenance for Select Patients (pts) with Metastatic Pancreatic Cancer (mPC) with (A) Homologous Recombination Deficiency (HRD)， (B) non-core HRD (ncHRD) and (C) Exceptional Response to Platinum

帕博利珠单抗和奥拉帕利（POLAR）看护赈济特定革新性PC患者的II期磨砺：患者患有（A）同源重组漏洞（HRD），（B）非中枢HRD（ncHRD）和（C）对铂的相等响应

报告内行：Wungki Park（好意思国・纽约）

胃肠说念间质瘤

提要号：LBA79

LENVAGIST - A multicentre， comparative， placebo (P)-controlled， double-blinded， phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib

LENVAGIST：一项多中心、对照、抚慰剂（P）对照、双盲、II期商议，探索仑伐替尼赈济伊马替尼和舒尼替尼失败后晚期胃肠说念间质瘤（GIST）患者的疗效

报告内行：Axel Le Cesne（法国・犹太城）

提要号：1722MO

Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)

奥雷巴替尼（HQP1351）赈济琥珀酸脱氢酶（SDH）漏洞型GIST患者的最新疗效恶果和潜在作用机制（MOA）

报告内行：邱海波（中山大学肿瘤防治中心）

提要号：1723MO

Axitinib plus avelumab in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) after failure of standard therapy: single-arm phase II study (AXAGIST)

阿昔替尼聚合avelumab赈济收受规范赈济失败后不成切除/革新性GIST患者：单臂II期商议（AXAGIST）

报告内行：Piotr Rutkowski（波兰・华沙）

备注：如有遗漏或任何问题，请给咱们留言。

更多ESMO精彩践诺，情怀医学界肿瘤频说念。

职守剪辑：Sheep

*医学界用功其发表践诺专科、可靠，但不合践诺的准确性作念出本心；请商量各方在罗致或以此看成有策画依据时另行核查。